doi:10.3969/j.issn.1673-8640.2023.12.016

Abstract

CLC Number:

R446.1

Figures/Tables 4

References 18

[1]	BITAR A, AUNG K M, WAI S N, et al. Vibrio cholerae derived outer membrane vesicles modulate the inflammatory response of human intestinal epithelial cells by inducing microRNA-146a[J]. Sci Rep, 2019, 9(1):7212. DOI
[2]	AWASTHI S P, CHOWDHURY N, NEOGI S B, et al. Development of a multiplex PCR assay for the detection of major virulence genes in Vibrio cholerae including non-O1 and non-O139 serogroups[J]. J Microbiol Methods, 2019, 157:54-58. DOI URL
[3]	VAN BONN S M, SCHRAVEN S P, SCHULDT T, et al. Chronic otitis media following infection by non-O1/non-O139 Vibrio cholerae:a case report and review of the literature[J]. Eur J Microbiol Immunol(Bp), 2020, 10(3):186-191.
[4]	MARAKI S, CHRISTIDOU A, ANASTASAKI M, et al. Non-O1,non-O139 Vibrio cholerae bacteremic skin and soft tissue infections[J]. Infect Dis(Lond), 2016, 48(3):171-176.
[5]	DE KEUKELEIRE S, HOSTE P, CRIVIT M, et al. Atypical manifestation of Vibrio cholerae:fear the water！[J]. Acta Clin Belg, 2018, 73(6):462-464. DOI URL
[6]	HIRSCH N, KAOOE E, GANGL A, et al. Phenotypic and genotypic properties of Vibrio cholerae non-O1,non-O139 isolates recovered from domestic ducks in Germany[J]. Microorganisms, 2020, 8(8):1104. DOI URL
[7]	LUO Y, WANG H, LIANG J, et al. Population structure and multidrug resistance of non-o1/non-O139 Vibrio cholerae in freshwater rivers in Zhejiang,China[J]. Microb Ecol, 2021, 82(2):319-333. DOI
[8]	SCHWARTZ K, HAMMERL J A, GOLLNER C, et al. Environmental and clinical strains of Vibrio cholerae non-o1,non-o139 from Germany possess similar virulence gene profiles[J]. Front Microbiol, 2019, 10:733. DOI URL
[9]	LAVIAD-SHITRIT S, SHARABY Y, IZHAKI I, et al. Antimicrobial susceptibility of environmental non-o1/non-O139 Vibrio cholerae isolates[J]. Front Microbiol, 2018, 9:1726. DOI URL
[10]	RAMAMURTHY T, NANDY R K, MUKHOPADHYAY A K, et al. Virulence regulation and innate host response in the pathogenicity of Vibrio cholerae[J]. Front Cell Infect Microbiol, 2020, 10:572096. DOI URL
[11]	SHANLEY J, KANJ A, EL Z S, et al. Non-O1,non-O139 Vibrio cholerae bacteremia in an urban academic medical center in the United States[J]. IDCases, 2019, 15:e00527. DOI URL
[12]	AZEEM A, NOGLES T, CHERZARD R. Septicemia secondary to Vibrio cholerae(non-O1/non-O139)in wound[J]. BMJ Case Rep, 2019, 12(10):e2301901.
[13]	BOGARI A A, ALSOLAMI B M, Al-HUSAYNI F, et al. Vibrio cholera bacteremia secondary to ascending cholangitis in a patient not on chemotherapy or immunosuppressants[J]. Cureus, 2021, 13(11):e19853.
[14]	ZMETER C, TABAJA H, SHARARA A I, et al. Non-O1,non-O139 Vibrio cholerae septicemia at a tertiary care center in Beirut,Lebanon;a case report and review[J]. J Infect Public Health, 2018, 11(5):601-604. DOI URL
[15]	DESHAYES S, DAUREL C, CATTOIR V, et al. Non-O1,non-O139 Vibrio cholerae bacteraemia:case report and literature review[J]. Springerplus, 2015, 4:575. DOI URL
[16]	LI X, WU Y, SUN X, et al. Non-O1/non-O139 Vibrio cholerae bacteraemia in mainland China from 2005 to 2019:clinical,epidemiological and genetic characteristics[J]. Epidemiol Infect, 2020, 148:e186. DOI URL
[17]	TSURUTA K, UEYAMA T, WATANABE T, et al. Intensive care management of a patient with necrotizing fasciitis due to non-O1/O139 Vibrio cholerae after traveling to Taiwan:a case report[J]. BMC Infect Dis, 2020, 20(1):618. DOI
[18]	LEPUSCHITZ S, BARON S, LARVOR E, et al. Phenotypic and genotypic antimicrobial resistance traits of Vibrio cholerae non-o1/non-o139 isolated from a large austrian lake frequently associated with cases of human infection[J]. Front Microbiol, 2019, 10:2600. DOI URL

患者编号	年龄/岁	性别	基础疾病	临床表现	治疗	疗程/d	预后	暴露史
例1	41	男	胰腺癌、肝转移瘤	胰腺癌术后化疗，入院第2天发热	头孢曲松	6	治愈	无
例2	56	男	肝硬化、肝性脑病、糖尿病	发热、黑便、呕血1 d	头孢他啶	8	治愈	无
例3	70	女	自身免疫性肝病、胆汁性肝硬化、高血压	发热2 d，双下肢红肿	亚胺培南-西司他丁	5	治愈	进食海鲜（海参、鲜虾）史
例4	39	男	急性肝衰竭、重症肺炎、乙肝、白塞病	双下肢水肿，皮肤黄，入院第3天发热	哌拉西林-他唑巴坦	6	放弃	无
例5	72	男	肝癌、肝硬化高血压、糖尿病	发热4 d，畏寒，排尿有烧灼感	哌拉西林-他唑巴坦	14	治愈	有不洁饮食史

患者编号	年龄/岁	性别	基础疾病	临床表现	治疗	疗程/d	预后	暴露史
例1	41	男	胰腺癌、肝转移瘤	胰腺癌术后化疗，入院第2天发热	头孢曲松	6	治愈	无
例2	56	男	肝硬化、肝性脑病、糖尿病	发热、黑便、呕血1 d	头孢他啶	8	治愈	无
例3	70	女	自身免疫性肝病、胆汁性肝硬化、高血压	发热2 d，双下肢红肿	亚胺培南-西司他丁	5	治愈	进食海鲜（海参、鲜虾）史
例4	39	男	急性肝衰竭、重症肺炎、乙肝、白塞病	双下肢水肿，皮肤黄，入院第3天发热	哌拉西林-他唑巴坦	6	放弃	无
例5	72	男	肝癌、肝硬化高血压、糖尿病	发热4 d，畏寒，排尿有烧灼感	哌拉西林-他唑巴坦	14	治愈	有不洁饮食史

编号	白细胞计数/（×10⁹/L）	中性粒细胞/%	高敏C反应蛋白/（mg/L）	降钙素原/（ng/mL）	血小板计数/（×10⁹/L）
例1	9.96↑	79.70↑	未查	未查	84.00↓
例2	6.09	88.80↑	31.00↑	0.84↑	36.00↓
例3	10.78↑	86.50↑	50.00↑	0.52↑	44.00↓
例4	11.42↑	82.50↑	12.13↑	3.96↑	105.00
例5	8.73	91.70↑	67.36↑	3.04↑	64.00↓

编号	白细胞计数/（×10⁹/L）	中性粒细胞/%	高敏C反应蛋白/（mg/L）	降钙素原/（ng/mL）	血小板计数/（×10⁹/L）
例1	9.96↑	79.70↑	未查	未查	84.00↓
例2	6.09	88.80↑	31.00↑	0.84↑	36.00↓
例3	10.78↑	86.50↑	50.00↑	0.52↑	44.00↓
例4	11.42↑	82.50↑	12.13↑	3.96↑	105.00
例5	8.73	91.70↑	67.36↑	3.04↑	64.00↓

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 18

Related Articles 15

Recommended Articles

Metrics

[1]	DUAN Pengcang, DONG Ruifang, LIU Xiaoman, CAO Yang, WANG Ruoxi. Correlation between serum Trx2，P-tau and total magnetic resonance imaging load score and cognitive function in patients with cerebral small vessel disease [J]. Laboratory Medicine, 2024, 39(1): 1-6.
[2]	ZHANG Miaomiao, DUAN Dongkui, YU Chun, WANG Lina. Expression and prognostic assessment value of miR-924 and SLC1A5 in lung cancer tissues [J]. Laboratory Medicine, 2024, 39(1): 13-18.
[3]	ZHANG Yang, ZHANG Dehe, TANG Shiyue, ZHANG Jun, WANG Jianming, CHEN Ling. Predictive value of soluble CD163 combined with Charlson index for esophageal variceal bleeding in patients with liver cirrhosis [J]. Laboratory Medicine, 2024, 39(1): 19-25.
[4]	LIU Bohan, LIU Yiwen, HE Yiqing, LU Renquan, DU Yan, ZHANG Guoliang, GUO Qian, GAO Feng, YANG Cuixia. Serum amphiregulin and mesothelin in auxiliary diagnosis of breast cancer [J]. Laboratory Medicine, 2024, 39(1): 26-30.
[5]	LAI Yuanyuan, HE Zhenye, SHEN Huaqing, LIN Yiteng, LIU Xijun, QI Jun, LIN Yongping. Roles of TAT，PIC and thromboelastography for assessing coagulation function in tumor patients [J]. Laboratory Medicine, 2024, 39(1): 43-46.
[6]	ZHANG Xiaoling, JIN Yao, LI Sufang, PENG Haiying. Synergistic diagnosis of THR mRNA and ALCAT1 in hyperthyroidism heart disease [J]. Laboratory Medicine, 2024, 39(1): 60-67.
[7]	. [J]. Laboratory Medicine, 2024, 39(1): 68-70.
[8]	LAN Jun, LU Shuting, YANG Jianrui. Roles of serum IL-26 and IL-27 levels in patients with colorectal cancer [J]. Laboratory Medicine, 2024, 39(1): 7-12.
[9]	JIANG Haoqin, XU Qianqian, XU Liming, GUAN Ming. Homogenization management and practice of clinical blood and body fluid determinations [J]. Laboratory Medicine, 2024, 39(1): 95-99.
[10]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[11]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[12]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[13]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[14]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[15]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.